Home
About Idogen
Idogen in brief
Management team
Board of directors
Scientific advisory board
Business concept
Horizon 2020
Career
R&D
Idogen´s technology
Research overview
Project portfolio
Research collaborations
Scientific publications
Investors
Financial reports
Stock information
Presentations
Financial calendar
Upcoming events
Investors contact
News & Media
News
Analyses
Interviews
Interview with Neil Thomas, Chief Business Officer in Idogen
Interview with Karin Hoogendoorn, Board member in Idogen
Interview with Steven Glazer, Chief Medical Officer in Idogen
Contact us
Search
Menu
Upcoming events
More events will be published shortly
Idogen develops tolerogenic cell therapy – individualised treatment for each patient
Scroll to top
